Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185381 | 0.93 | UTS2R (0.47) | UTS2RENPP2CHRNA7HTR3AHDAC1 | |
| SCHEMBL10186507 | 0.91 | PRSS12 (0.46) | UTS2RENPP2CHRNA7HDAC1PRSS12 | |
| SCHEMBL10185635 | 0.90 | NAMPT (0.45) | UTS2RHDAC1PDE4APDE4BPDE4C | |
| SCHEMBL10185348 | 0.88 | DGAT1 (0.49) | UTS2RCHRNA7HTR3AHDAC1DGAT1 | |
| SCHEMBL10185074 | 0.88 | UTS2R (0.40) | UTS2RCHRNA7HTR3ADGAT1SOAT1 | |
| SCHEMBL10186271 | 0.87 | UTS2R (0.42) | UTS2RCHRNA7HTR3AHDAC1DGAT1 | |
| SCHEMBL10185719 | 0.86 | UTS2R (0.46) | UTS2RCHRNA7HTR3AHDAC1AR | |
| SCHEMBL10186284 | 0.85 | L3MBTL1 (0.49) | ENPP2CHRNA7DGAT1PDE4APDE4B | |
| SCHEMBL10185384 | 0.84 | CHRNA7 (0.42) | ENPP2CHRNA7HTR3ADGAT1PDE4A | |
| SCHEMBL10184522 | 0.84 | CHRNA7 (0.40) | UTS2RCHRNA7HTR3AHDAC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | UTS2R 2678/4885ENPP2 812/4885CHRNA7 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.